Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Operating Income: 2020-2024

Historic Operating Income for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$176.3 million.

  • NewAmsterdam Pharma Co N.V's Operating Income fell 120.55% to -$55.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.9 million, marking a year-over-year decrease of 10.21%. This contributed to the annual value of -$176.3 million for FY2024, which is 3.65% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Operating Income of -$176.3 million as of FY2024, which was up 3.65% from -$183.0 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Operating Income registered a high of -$3.6 million during FY2022, and its lowest value of -$183.0 million during FY2023.
  • Its 3-year average for Operating Income is -$120.9 million, with a median of -$176.3 million in 2024.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Operating Income skyrocketed by 89.83% in 2022 and then slumped by 5,043.86% in 2023.
  • Yearly analysis of 5 years shows NewAmsterdam Pharma Co N.V's Operating Income stood at -$6.2 million in 2020, then tumbled by 464.26% to -$35.0 million in 2021, then surged by 89.83% to -$3.6 million in 2022, then plummeted by 5,043.86% to -$183.0 million in 2023, then grew by 3.65% to -$176.3 million in 2024.